Genentech settles on Cabilly
Executive Summary
Genentech resolves its long-standing dispute with MedImmune over its Cabilly patent, which relates to the process for producing antibodies, the biotech announces. MedImmune, which licenses the patent along with Johnson & Johnson, ImClone and Abbott, filed suit in 2003 challenging the patent, but it was not until a decision by the U.S. Supreme Court in January that the firm gained the necessary legal standing (1"The Pink Sheet," Jan. 15, 2007, p. 7). Under the settlement, the manufacturer of Synagis (palivizumab) can obtain licenses for certain additional pipeline products under the Cabilly patent family, including motavizumab. Financial terms of the settlement were not disclosed